Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets

 Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets

Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Shots:

  • Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis
  • Novartis to get exclusive license rights of ZFP-TFs for three genes including ASD and intellectual disability for neurodevelopmental disorders also holds an option to license Sangamo’s AAVs. The company will perform research activities, investigational new drug-enabling studies clinical development, related regulatory interactions, manufacturing and, global commercialization
  • ZFP-TFs is a genome regulation technology delivered using AAVs and will be utilized by the partnering companies to upregulate, or activate, the expression of genes expressed in individuals with certain types of neurodevelopmental disorders

Click here to read full press release/ article | Ref: Businesswire | Image: Healthworld

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post